

B1  
3. (Amended) The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid of SEQ ID NO:19.

my 11-26-02  
B2  
4. The polypeptide of claim 1, wherein the amino acid sequence of said variant comprises a conservative amino acid substitution.

B3  
38. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically-acceptable carrier.

B4  
41. A kit comprising in one or more containers, the pharmaceutical composition of claim 38.

Sub  
13  
B5  
50. (New) A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:19.

51. (New) The method of claim 50 wherein the cell is a bacterial cell.

52. (New) The method of claim 50 wherein the cell is an insect cell.

53. (New) The method of claim 50 wherein the cell is a yeast cell.

54. (New) The method of claim 50 wherein the cell is a mammalian cell.

*Pursuant to 37 C.F.R. 1.121(c)(1)(ii), a version marked to show claim changes made appears as Appendix A of this Amendment.*

#### RESPONSE TO RESTRICTION REQUIREMENT

In response to the July 3, 2002, Restriction Requirement, Applicants elect Group X, claims 1-4, 38 and 41, drawn to polypeptides and variants, classified in class 530, subclass 350.